Efficacy, Safety, and Kinetics of Naturally Selected Anti‐ CD7 CAR ‐T Cell Therapy in T‐ ALL / LBL With CNS Leukemia
Year: 2026
Type: article
Abstract: To the Editor, Central nervous system leukemia (CNSL) remains one of the most challenging manifestations of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL).Despite intensive therapy, outcomes after CNS relapse remain poor and treatment options are limited [1-3].CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated remarkable efficacy in R/R T-ALL/LBL, with complete remission (CR) rates approaching 90% [4][5][6][7].However, whether CD7 CAR-T cells can effectively traffic to and eradicate CNSL without excessive neurotoxicity remains poorly defined.
Source: American Journal of Hematology
DOI: 10.1002/ajh.70482
Institutions: Beijing Dao Pei Hospital, Hebei Yanda Ludaopei Hospital
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7204186915